Literature DB >> 16117712

Yellow fever vaccine.

Thomas P Monath1.   

Abstract

Yellow fever, a mosquito-borne viral hemorrhagic fever, is one of the most lethal diseases of humankind. The etiologic agent is the prototype member of the genus Flavivirus, family Flaviviridae, a group of small, enveloped, positive-sense, single-strand RNA viruses. Approximately one in seven people who become infected develop a rapidly progressive illness, with hepatitis, renal failure, hemorrhage and cardiovascular shock, with a case fatality rate of 20-50%. Yellow fever occurs in sub-Saharan Africa and tropical South America, where it remains a continuing public health problem of varying magnitude, depending on the level of vaccination coverage in the human population and cyclical, ecologic and climatic factors that influence virus transmission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16117712     DOI: 10.1586/14760584.4.4.553

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  85 in total

1.  Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.

Authors:  Rajendra Raut; Kizzmekia S Corbett; Rashika N Tennekoon; Sunil Premawansa; Ananda Wijewickrama; Gayani Premawansa; Piotr Mieczkowski; Claudia Rückert; Gregory D Ebel; Aruna D De Silva; Aravinda M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-05       Impact factor: 11.205

2.  Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Authors:  S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Authors:  Celestine N Wanjalla; Elizabeth J Faul; Emily A Gomme; Matthias J Schnell
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

4.  Neuropathogenesis and neurovirulence of live flaviviral vaccines in monkeys.

Authors:  Inessa Levenbook; Ken Draper
Journal:  J Virol       Date:  2009-05       Impact factor: 5.103

5.  Analysis of TK and C18L genes of wild-type and cell culture passaged camelpox virus.

Authors:  Muaz M Abdellatif; Bashir Salim; Awad A Ibrahim; Tigani Asil; Abdelmalik I Khalafalla
Journal:  Virol Sin       Date:  2013-07-24       Impact factor: 4.327

Review 6.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Authors:  Bali Pulendran
Journal:  Nat Rev Immunol       Date:  2009-09-18       Impact factor: 53.106

Review 7.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

8.  Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.

Authors:  Eddie A James; Rebecca E LaFond; Theresa J Gates; Duy T Mai; Uma Malhotra; William W Kwok
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

10.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.